Here are the latest stories being discussed in biopharma today:
Eli Lilly Ends $13.5M Settlement After Federal Judge’s Decision
Eli Lilly and insulin users have scrapped a settlement following a federal judge’s ruling that denied a class certification for their lawsuit. Originating from accusations of price inflation in a 2017 lawsuit, Lilly and the plaintiffs reached a $13.5 million deal in 2020 wherein Lilly would also cap out-of-pocket insulin costs for four years. This month, both parties announced they would not proceed with the settlement after the judge’s decision.
GSK Unveils Long-Term Shingrix Data Amid Competition Heat
As competition intensifies, GSK has revealed Shingrix vaccine’s long-term efficacy data against shingles. The vaccine demonstrated 82% effectiveness after 11 years, according to a study involving adults aged 50 and above. In older adults aged 70 and above, an efficacy rate of 73% was maintained between six and 11 years post-vaccination.
Survey Reveals ChatGPT Use Prohibited in Most Pharma & Biotech Firms
A survey has discovered that a majority of pharma and biotech companies restrict or prohibit the use of ChatGPT amongst their employees, with 65% of the top 20 pharma companies restricting its utilization. Critical concerns cited include security and potential internal data leaks. This caution extends beyond the pharma industry, with leading tech and finance businesses also banning ChatGPT.
Fujifilm Eyes Boost in Manufacturing Revenues through ADC Trust
Fujifilm’s subsidiary, Fujifilm Diosynth Biotechnologies, expects vigorous investments in the next three years from its parent company to enhance revenues. The Contract Development and Manufacturing Organization (CDMO) plans to capitalize on antibody-drug conjugates’ high demand and establish trust through reliable client service.
Sanofi’s Oncology Cuts Affect IGM’s Potential Biobucks
Sanofi’s adjustments in its oncology plans have led to a loss of approximately $3 billion in potential biobucks for partner IGM Biosciences. The French pharma giant refined its partnership agreement with IGM, removing three targets in their oncology venture, cutting potential earnings from a $6.15 billion pact.
Lilly Proposes Zepbound Label Expansion into Sleep Apnea
Eli Lilly’s weight loss drug, Zepbound, successfully met primary endpoints in two Phase 3 trials involving adults with obesity and obstructive sleep apnea. The positive results set the stage for the potential approval of the drug for the breathing disorder. Lilly plans to submit the data to the FDA and other countries by mid-year.
